SCHEMBL6452864

SCHEMBL6452864

C=CCC(C)(C(=O)O)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 1/20 0.32
TET2 Q6N021 1/20 0.31
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30
HIF1A Q16665 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7703176 0.81 HTT (0.38) HTT
SCHEMBL16908691 0.78 TSHR (0.41) TSHRALDH1A1HTTCYP2D6CYP2C19
SCHEMBL16908674 0.78 TSHR (0.37) TSHRALDH1A1HTTCYP2D6CYP2C19
SCHEMBL27730182 0.78 TSHR (0.31) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL9652201 0.77
SCHEMBL1598539 0.76
SCHEMBL23971267 0.75 MAPK1 (0.39) TSHRALDH1A1HIF1AMAPT
Ammonia Solution, Strong SCHEMBL28496426 0.74 ALDH1A1 (0.34) TSHRALDH1A1
SCHEMBL28914056 0.74 ALDH1A1 (0.34) TSHRALDH1A1TET2MAPT
SCHEMBL30390434 0.73 ALDH1A1 (0.39) TSHRALDH1A1HTTTET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020039769-A1 Process for preparing optically active 3,3,3- trifluoromethyl-2-alkylpropionic acid derivatives LONZA AG 2002-04-04 US claimed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
EP-4143189-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-03-08 EP disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed
EP-1155138-B1 METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES LONZA AG (CH) 2005-01-05 EP disclosed
US-6599721-B2 Chemical intermediates; hydrolysis using hydrolases LONZA AG (CH) 2003-07-29 US disclosed
US-6599721-B2 Chemical intermediates; hydrolysis using hydrolases LONZA AG (CH) 2003-07-29 US disclosed
US-6599721-B2 Chemical intermediates; hydrolysis using hydrolases LONZA AG (CH) 2003-07-29 US disclosed
US-20020039769-A1 Process for preparing optically active 3,3,3- trifluoromethyl-2-alkylpropionic acid derivatives LONZA AG 2002-04-04 US disclosed
US-20020039769-A1 Process for preparing optically active 3,3,3- trifluoromethyl-2-alkylpropionic acid derivatives LONZA AG 2002-04-04 US disclosed
US-20020039769-A1 Process for preparing optically active 3,3,3- trifluoromethyl-2-alkylpropionic acid derivatives LONZA AG 2002-04-04 US disclosed
EP-1155138-A2 METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES Lonza AG (CH) 2001-11-21 EP disclosed
WO-2000050623-A3 METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES LONZA AG (CH) 2001-04-19 WO disclosed
WO-2000050623-A2 METHOD FOR PREPARING OPTICALLY ACTIVE 3,3,3-TRIFLUOROMETHYL-2-ALKYL PROPIONIC ACID DERIVATIVES LONZA AG (CH) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 TSHR 1815/4885ALDH1A1 2537/4885HTT 3084/4885
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 TSHR 1815/4885ALDH1A1 2537/4885HTT 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.